Monte Rosa Therapeutics, Inc. GLUE Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s cash ratio?
- Monte Rosa Therapeutics, Inc. (GLUE) reported cash ratio of 2.3× in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s cash ratio changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s cash ratio increased by 69.7% year-over-year, from 1.3× to 2.3×.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s cash ratio?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s cash ratio has grown at a 7.3% compound annual growth rate (CAGR), from 1.4× to 2×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.